Screening & Prevention — MCQs
On this page
A 41-year-old woman presents requesting information about breast cancer screening. Her mother was diagnosed with breast cancer at age 58 and her maternal aunt at age 62. She has no personal history of breast disease and clinical examination is normal. She asks whether she is eligible for early screening. What is the most appropriate initial response?
A 73-year-old man attends for review. He received his NHS bowel screening kit but has not returned it. He mentions he had a colonoscopy 7 years ago for rectal bleeding which showed diverticular disease but no polyps or cancer. He feels the screening is unnecessary given his previous investigation. What is the most appropriate advice?
A 27-year-old woman attends requesting cervical screening. She last had cervical screening 4 years ago which showed hrHPV negative. She has been in a stable relationship for 2 years and has no symptoms. She is concerned because her new partner has disclosed previous genital warts. What is the most appropriate action regarding cervical screening?
A 65-year-old woman attends for NHS breast screening. She had a wide local excision with adjuvant radiotherapy for left breast ductal carcinoma in situ 8 years ago. She has been disease-free since completion of treatment. Her last mammogram was 3 years ago. She is otherwise well and takes no regular medications. What is the most appropriate management of her breast screening?
A 71-year-old woman with type 2 diabetes for 15 years attends for review. She mentions she has not attended for diabetic retinopathy screening for 3 years as she "forgot about the appointments." Her recent HbA1c is 76 mmol/mol and she has background diabetic retinopathy documented from 4 years ago. She takes metformin, gliclazide, and atorvastatin. Fundoscopy today shows dot and blot haemorrhages bilaterally with several hard exudates temporal to the left macula. What is the most appropriate action regarding her diabetic retinopathy screening?
A 68-year-old man attends following detection of a 3.2 cm abdominal aortic aneurysm on his NHS AAA screening ultrasound. He is asymptomatic. He has type 2 diabetes, hypertension, and continues to smoke 10 cigarettes daily. His current medications include metformin, ramipril, amlodipine, and atorvastatin. What is the most important lifestyle intervention that will reduce his risk of aneurysm expansion and rupture?
A 34-year-old woman who is 10 weeks pregnant with her second child attends for booking. Her first pregnancy 3 years ago was uncomplicated. She declined antenatal screening at that time for personal reasons. She has no family history of genetic conditions. She now wishes to discuss screening options. Which statement regarding combined first trimester screening for Down's syndrome, Edwards' syndrome and Patau's syndrome is correct?
A 43-year-old man with severe mental illness (schizophrenia) attends for his annual physical health check. He takes olanzapine 15 mg daily and has gained significant weight over the past year. His BMI is now 34 kg/m², BP 148/92 mmHg, and blood tests show HbA1c 48 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L, and triglycerides 3.8 mmol/L. He smokes 15 cigarettes daily. According to the Lester UK Adaptation of the Positive Cardiometabolic Health Resource, what is the recommended frequency for monitoring metabolic parameters in patients on antipsychotic medication after the first year?
A 49-year-old woman attends with her NHS breast screening invitation letter. She had a benign fibroadenoma excised 10 years ago and is now concerned about radiation exposure from mammography. She asks whether the benefits of screening outweigh the harms. Which statement most accurately represents the evidence regarding breast screening in the NHS programme?
A 57-year-old man attends for an NHS Health Check. He works night shifts as a security guard and admits to minimal physical activity. His BMI is 32 kg/m², BP 136/84 mmHg, and he has impaired fasting glucose at 6.3 mmol/L. HbA1c is 43 mmol/mol. His QRISK3 score is 9%. He is keen to reduce his diabetes risk. According to NICE guidance, which intervention has the strongest evidence for preventing progression to type 2 diabetes in people with non-diabetic hyperglycaemia?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 111: A 41-year-old woman presents requesting information about breast cancer screening. Her mother was diagnosed with breast cancer at age 58 and her maternal aunt at age 62. She has no personal history of breast disease and clinical examination is normal. She asks whether she is eligible for early screening. What is the most appropriate initial response?
- A. Arrange annual mammography privately until she reaches NHS screening age
- B. She meets criteria for referral to genetics service for risk assessment
- C. She should commence routine NHS breast screening immediately
- D. She does not meet criteria for early screening but should continue breast awareness (Correct Answer)
- E. Offer baseline ultrasound scan and review family history at age 45
Explanation: ***She does not meet criteria for early screening but should continue breast awareness*** - Her family history (mother diagnosed at age **58**, maternal aunt at age **62**) falls into the **near-population risk** category and does not meet the threshold for enhanced screening or referral to genetics services, which typically require earlier onset diagnoses or more extensive family history. - The most appropriate advice is to promote **breast awareness** and explain that she will be invited for routine **NHS breast screening** when she reaches the eligible age (typically 50-53). *Arrange annual mammography privately until she reaches NHS screening age* - Suggesting private annual mammography for a woman at near-population risk is not evidence-based and may lead to **unnecessary radiation exposure**, **anxiety** from false positives, and **over-diagnosis** without clear benefit. - Current guidelines do not support private screening for this level of risk, as the harms outweigh the benefits. *She meets criteria for referral to genetics service for risk assessment* - Referral to a **genetics service** usually requires a stronger family history, such as a **first-degree relative** diagnosed with breast cancer under age 40, or multiple cases of early-onset breast/ovarian cancer within the family. - Her family history does not indicate a sufficiently high **hereditary risk** to warrant a genetics referral at this time. *She should commence routine NHS breast screening immediately* - The **NHS Breast Screening Programme** typically invites women for their first mammogram between the ages of **50 and 53**, not at age 41. - Starting routine screening immediately is only indicated for women with a significantly **higher risk** profile, which is not present in this case. *Offer baseline ultrasound scan and review family history at age 45* - An **ultrasound scan** is generally used as a diagnostic tool for specific breast concerns or as an adjunct to mammography for dense breasts, rather than as a primary **screening modality** for asymptomatic women at population risk. - There is no evidence-based guideline to offer a baseline ultrasound or specifically review family history at age 45 in this risk group without new clinical developments.
Question 112: A 73-year-old man attends for review. He received his NHS bowel screening kit but has not returned it. He mentions he had a colonoscopy 7 years ago for rectal bleeding which showed diverticular disease but no polyps or cancer. He feels the screening is unnecessary given his previous investigation. What is the most appropriate advice?
- A. Agree that screening is unnecessary given recent normal colonoscopy
- B. Advise him to complete the screening kit as previous colonoscopy does not replace screening (Correct Answer)
- C. Arrange surveillance colonoscopy instead of faecal immunochemical testing
- D. Advise screening is only needed if he develops new symptoms
- E. Explain he is now outside the screening age range and will not receive further invitations
Explanation: ***Advise him to complete the screening kit as previous colonoscopy does not replace screening***- A **colonoscopy** performed 7 years ago does not provide lifetime protection or replace the **NHS bowel cancer screening programme**, as new lesions can develop in the interval.- The **Faecal Immunochemical Test (FIT)** is designed to detect **asymptomatic** early-stage cancer and polyps, which may have developed since his last investigation.*Agree that screening is unnecessary given recent normal colonoscopy*- A colonoscopy from 7 years ago is not considered "recent" enough to exclude current pathology, and **diverticular disease** does not protect against malignancy.- Standard guidelines state that screening should continue regardless of previous **symptomatic investigations** unless the patient is currently under a high-intensity surveillance program.*Arrange surveillance colonoscopy instead of faecal immunochemical testing*- **Surveillance colonoscopy** is reserved for high-risk patients with previous **adenomas**, polyps, or inflammatory bowel disease, which this patient does not have.- Arranging a colonoscopy for an asymptomatic patient with a history of only **diverticular disease** is clinically unnecessary and carries higher procedural risks than a **FIT test**.*Advise screening is only needed if he develops new symptoms*- The primary goal of screening is **primary prevention** and the detection of disease in **asymptomatic** individuals to improve survival rates.- Waiting for **symptoms** such as weight loss or change in bowel habits often means the cancer has reached a more advanced, less treatable stage.*Explain he is now outside the screening age range and will not receive further invitations*- In England, the **NHS bowel screening** age range currently includes individuals up to the age of **74**, meaning this 73-year-old is still eligible for routine invitations.- Even after age 74, patients can take the initiative to **self-refer** and request a screening kit every two years, so he should not be told screening is over.
Question 113: A 27-year-old woman attends requesting cervical screening. She last had cervical screening 4 years ago which showed hrHPV negative. She has been in a stable relationship for 2 years and has no symptoms. She is concerned because her new partner has disclosed previous genital warts. What is the most appropriate action regarding cervical screening?
- A. Arrange cervical screening now due to new sexual partner
- B. Reassure and arrange cervical screening at 5 years from last screen (Correct Answer)
- C. Perform cervical screening and test specifically for HPV types 6 and 11
- D. Refer to genitourinary medicine for HPV vaccination
- E. Arrange colposcopy referral given partner's HPV history
Explanation: ***Reassure and arrange cervical screening at 5 years from last screen***- In the UK, women aged **25-49** are screened every **5 years**; since her last screen was **hrHPV negative** 4 years ago, she is not due for another year.- A **change in sexual partner** or a partner's history of genital warts is not a clinical indication to perform early cervical screening in an asymptomatic patient.*Arrange cervical screening now due to new sexual partner*- Screening intervals are determined by the **hrHPV status** of the previous test and age, not by the frequency or identity of sexual partners.- Performing tests earlier than the **recommended interval** increases the risk of identifying transient infections that would otherwise resolve spontaneously.*Perform cervical screening and test specifically for HPV types 6 and 11*- Cervical screening specifically targets **high-risk HPV (hrHPV)** types that are oncogenic, whereas types **6 and 11** are low-risk types responsible for genital warts.- Testing for low-risk HPV types provides no benefit in **cervical cancer prevention** and is not part of the standard screening protocol.*Refer to genitourinary medicine for HPV vaccination*- The **HPV vaccine** is most effective when given prior to sexual debut, and while it can be given later, a partner's history of warts is not a standard trigger for **catch-up vaccination** at age 27.- The primary concern here is the **screening schedule**, and vaccination does not replace or alter the need for routine cervical screening.*Arrange colposcopy referral given partner's HPV history*- **Colposcopy** is a diagnostic tool used for investigating positive hrHPV results or abnormal cytology, neither of which apply to this patient.- **Genital warts** in a partner do not increase the risk of high-grade cervical dysplasia in a way that bypasses standard screening and necessitates direct referral.
Question 114: A 65-year-old woman attends for NHS breast screening. She had a wide local excision with adjuvant radiotherapy for left breast ductal carcinoma in situ 8 years ago. She has been disease-free since completion of treatment. Her last mammogram was 3 years ago. She is otherwise well and takes no regular medications. What is the most appropriate management of her breast screening?
- A. Continue routine NHS breast screening every 3 years until age 70 (Correct Answer)
- B. Discharge from NHS breast screening and arrange annual symptomatic surveillance mammography
- C. Refer to breast surgery for clinical assessment before continuing screening
- D. Offer MRI surveillance annually in addition to mammography
- E. Extend screening interval to 5 years due to previous treatment
Explanation: ***Continue routine NHS breast screening every 3 years until age 70*** - In the UK, individuals treated for **ductal carcinoma in situ (DCIS)** or invasive cancer typically return to the **NHS Breast Screening Programme (NHSBSP)** after 5 years of specialist follow-up, if they are within the eligible age range. - As she is 65 years old and 8 years post-treatment, she has completed her enhanced surveillance and should continue **3-yearly mammograms** as part of the routine screening program until the upper age limit of 70. *Discharge from NHS breast screening and arrange annual symptomatic surveillance mammography* - **Annual clinical surveillance** is usually provided by hospital teams for the initial 5 years post-diagnosis, not indefinitely or in place of routine screening after this period. - **Symptomatic surveillance** is not a standard program for asymptomatic individuals; patients who are disease-free and beyond 5 years post-treatment should integrate back into population-based screening. *Refer to breast surgery for clinical assessment before continuing screening* - For an asymptomatic patient who has remained **disease-free** for 8 years, a routine referral to **breast surgery** for assessment before continuing screening is unnecessary. - Routine screening is managed by the **NHSBSP**, with referrals to specialists only initiated if a new abnormality is detected during screening. *Offer MRI surveillance annually in addition to mammography* - **Annual MRI surveillance** is typically reserved for women at **very high risk** of breast cancer, such as those with BRCA1/2 mutations or a strong family history, which is not indicated for this case of DCIS. - For most women with a history of DCIS and no other high-risk factors, **mammography alone** remains the primary and sufficient imaging modality for long-term follow-up within a screening context. *Extend screening interval to 5 years due to previous treatment* - There are no guidelines supporting an **extended screening interval** to 5 years for patients with a history of DCIS; the standard **3-year interval** is maintained. - A history of breast cancer or DCIS indicates a slightly **increased lifetime risk** of developing another breast cancer, reinforcing the need for regular, timely screening, not less frequent.
Question 115: A 71-year-old woman with type 2 diabetes for 15 years attends for review. She mentions she has not attended for diabetic retinopathy screening for 3 years as she "forgot about the appointments." Her recent HbA1c is 76 mmol/mol and she has background diabetic retinopathy documented from 4 years ago. She takes metformin, gliclazide, and atorvastatin. Fundoscopy today shows dot and blot haemorrhages bilaterally with several hard exudates temporal to the left macula. What is the most appropriate action regarding her diabetic retinopathy screening?
- A. Arrange routine diabetic retinopathy screening appointment within 3 months
- B. Refer urgently to ophthalmology for assessment within 1 week
- C. Continue annual diabetic retinopathy screening through the screening programme
- D. Refer to ophthalmology within 6 weeks for assessment of maculopathy (Correct Answer)
- E. Arrange repeat screening in 6 months once glycaemic control improves
Explanation: ***Refer to ophthalmology within 6 weeks for assessment of maculopathy*** - The presence of **hard exudates** temporal to the left macula indicates **diabetic maculopathy**, a sight-threatening condition requiring specialist ophthalmological assessment. - Current guidelines recommend referral to hospital eye services for assessment within **6 weeks** for diabetic maculopathy, due to the risk to central vision. *Arrange routine diabetic retinopathy screening appointment within 3 months* - This action is insufficient because the patient has already demonstrated signs of **diabetic maculopathy**, which constitutes **sight-threatening retinopathy**. - A 3-month delay is inappropriate for an identified maculopathy, which requires a more urgent specialist review to prevent further vision loss. *Refer urgently to ophthalmology for assessment within 1 week* - **Urgent 1-week referral** is typically reserved for more severe, rapidly progressing conditions such as **proliferative diabetic retinopathy** or vitreous hemorrhage. - While serious, the described stable hard exudates near the macula usually fall into the 6-week referral category, rather than an immediate 1-week emergency. *Continue annual diabetic retinopathy screening through the screening programme* - Annual screening is appropriate for patients with **no retinopathy** or mild background changes without macula involvement. - This patient's fundoscopy findings have progressed beyond background retinopathy to **diabetic maculopathy**, necessitating specialist ophthalmic management rather than routine screening. *Arrange repeat screening in 6 months once glycaemic control improves* - While improving the **HbA1c of 76 mmol/mol** (9.1%) is important, it must not delay the assessment and management of existing **diabetic maculopathy**. - Rapid optimization of blood glucose can sometimes lead to a **transient worsening** of retinopathy, making prompt specialist assessment even more critical.
Question 116: A 68-year-old man attends following detection of a 3.2 cm abdominal aortic aneurysm on his NHS AAA screening ultrasound. He is asymptomatic. He has type 2 diabetes, hypertension, and continues to smoke 10 cigarettes daily. His current medications include metformin, ramipril, amlodipine, and atorvastatin. What is the most important lifestyle intervention that will reduce his risk of aneurysm expansion and rupture?
- A. Smoking cessation (Correct Answer)
- B. Weight reduction to achieve BMI <25 kg/m²
- C. Reducing dietary sodium intake to <6g daily
- D. Increasing physical activity to 150 minutes weekly
- E. Adopting a Mediterranean diet pattern
Explanation: ***Smoking cessation*** - **Smoking** is the most significant modifiable risk factor for the development, growth, and **rupture** of abdominal aortic aneurysms (AAA). - Current smokers exhibit **expansion rates** nearly double those of non-smokers, making cessation the highest priority for slowing disease progression. *Weight reduction to achieve BMI <25 kg/m²* - While **weight management** is beneficial for overall cardiovascular health and metabolic syndrome, it has a weaker correlation with **AAA expansion** than tobacco use. - This patient already has established vascular disease (AAA) and hypertension, where **smoking status** is the more immediate driver of aortic wall degradation. *Reducing dietary sodium intake to <6g daily* - Sodium restriction helps manage **hypertension**, which is a risk factor for AAA development, but it does not independently stop aneurysm growth as effectively as quitting smoking. - Blood pressure control is vital for general **cardiovascular risk**, yet smoking cessation provides a more direct benefit specifically for the **aortic wall stability**. *Increasing physical activity to 150 minutes weekly* - **Exercise** is essential for maintaining arterial health and reducing overall mortality, but it is not specifically proven to prevent **aneurysm rupture** once a 3.2 cm AAA exists. - Physical activity should be encouraged, but it must be secondary to eliminating the **collagen-degrading** effects of cigarette smoke. *Adopting a Mediterranean diet pattern* - The **Mediterranean diet** is excellent for lipid profiles and reducing the risk of myocardial infarction, but it has no specific evidence for reducing **AAA growth rates**. - While part of primary cardiovascular prevention, it does not address the **proteolytic activity** in the aortic wall exacerbated by smoking.
Question 117: A 34-year-old woman who is 10 weeks pregnant with her second child attends for booking. Her first pregnancy 3 years ago was uncomplicated. She declined antenatal screening at that time for personal reasons. She has no family history of genetic conditions. She now wishes to discuss screening options. Which statement regarding combined first trimester screening for Down's syndrome, Edwards' syndrome and Patau's syndrome is correct?
- A. It should be performed between 11+2 and 14+1 weeks gestation (Correct Answer)
- B. It includes measurement of nuchal translucency, beta-hCG, and alpha-fetoprotein
- C. A high-risk result (≥1 in 150) automatically leads to amniocentesis
- D. It has a detection rate of approximately 99% for Down's syndrome
- E. Crown-rump length must be between 35-70 mm for accurate nuchal translucency measurement
Explanation: ***It should be performed between 11+2 and 14+1 weeks gestation*** - The **combined test** for Down's, Edwards', and Patau's syndromes is optimally performed within this specific gestational window. - This timeframe, typically corresponding to a **crown-rump length (CRL)** of **45mm to 84mm**, ensures accurate measurement of **nuchal translucency** and biochemical markers. *It includes measurement of nuchal translucency, beta-hCG, and alpha-fetoprotein* - The combined first-trimester screening includes **nuchal translucency**, **free beta-hCG**, and **PAPP-A (Pregnancy-Associated Plasma Protein-A)**. - **Alpha-fetoprotein (AFP)** is a component of the second-trimester quadruple screen, not the first-trimester combined screening. *A high-risk result (≥1 in 150) automatically leads to amniocentesis* - A high-risk result indicates a higher probability, but diagnostic procedures like **amniocentesis** or **CVS (Chorionic Villus Sampling)** are always optional and require informed parental decision. - If diagnostic testing is chosen in the first trimester, **CVS** is typically performed, whereas **amniocentesis** is usually performed from 15 weeks gestation onwards. *It has a detection rate of approximately 99% for Down's syndrome* - The combined first-trimester screening typically has a detection rate of **85-90%** for Down's syndrome. - A detection rate of approximately **99%** is more characteristic of **Non-Invasive Prenatal Testing (NIPT)**, which screens cell-free fetal DNA. *Crown-rump length must be between 35-70 mm for accurate nuchal translucency measurement* - For an accurate **nuchal translucency (NT)** measurement, the **crown-rump length (CRL)** of the fetus should be between **45mm and 84mm**. - A CRL outside this range can lead to inaccurate NT results and may necessitate alternative screening methods.
Question 118: A 43-year-old man with severe mental illness (schizophrenia) attends for his annual physical health check. He takes olanzapine 15 mg daily and has gained significant weight over the past year. His BMI is now 34 kg/m², BP 148/92 mmHg, and blood tests show HbA1c 48 mmol/mol, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L, and triglycerides 3.8 mmol/L. He smokes 15 cigarettes daily. According to the Lester UK Adaptation of the Positive Cardiometabolic Health Resource, what is the recommended frequency for monitoring metabolic parameters in patients on antipsychotic medication after the first year?
- A. Every 3 months
- B. Every 6 months
- C. Annually (Correct Answer)
- D. Every 2 years
- E. Only if symptomatic
Explanation: ***Annually***- The **Lester UK Adaptation** guidelines recommend **annual monitoring** of metabolic parameters for patients on antipsychotic medication *after the first year* of treatment.- This systematic review includes assessing **BMI**, **blood pressure**, **HbA1c**, and **lipid profile** to mitigate the increased cardiovascular risk associated with these medications.*Every 3 months*- This frequency is typically reserved for the **initial phase** (first 12 weeks) of starting a new antipsychotic to detect rapid metabolic changes.- While crucial for early detection, it is not the recommended *long-term* monitoring frequency *after the first year* according to the **Lester Tool**.*Every 6 months*- Monitoring **every 6 months** is not the standardized long-term frequency recommended by the **Lester UK Adaptation** for patients *after the first year* on antipsychotics.- While some high-risk patients might benefit from this, the routine guideline emphasizes a comprehensive **annual physical health review**.*Every 2 years*- This interval is far too infrequent given the high risk of **metabolic syndrome** and **cardiovascular disease** associated with second-generation antipsychotics like **olanzapine**.- Delaying checks to every 2 years would result in missing critical windows for managing evolving **dyslipidaemia** or **impaired glucose regulation**.*Only if symptomatic*- Metabolic complications like **hypertension**, **hypercholesterolaemia**, and **diabetes** are often **asymptomatic** until significant damage has occurred.- Proactive and systematic screening, rather than reactive monitoring based on symptoms, is essential for early intervention and prevention of **cardiovascular morbidity**.
Question 119: A 49-year-old woman attends with her NHS breast screening invitation letter. She had a benign fibroadenoma excised 10 years ago and is now concerned about radiation exposure from mammography. She asks whether the benefits of screening outweigh the harms. Which statement most accurately represents the evidence regarding breast screening in the NHS programme?
- A. For every 10,000 women screened for 20 years, approximately 40 breast cancer deaths are prevented (Correct Answer)
- B. Approximately 1 in 4 screen-detected breast cancers represents overdiagnosis
- C. Screening reduces breast cancer mortality by approximately 50% in those who attend
- D. The false positive rate requiring further assessment is less than 2%
- E. Radiation exposure from screening causes approximately 10 breast cancer cases per 10,000 women screened
Explanation: ***For every 10,000 women screened for 20 years, approximately 40 breast cancer deaths are prevented*** - According to the **Marmot Review**, inviting 10,000 women for screening over 20 years prevents approximately **43 breast cancer deaths**, which is statistically significant. - This data forms the primary evidence for the **benefit-to-harm ratio** communicated to patients in the NHS screening programme leaflets. *Approximately 1 in 4 screen-detected breast cancers represents overdiagnosis* - Evidence suggests that approximately **3 out of every 4** screen-detected cases are clinically significant, meaning overdiagnosis occurs in about **19%** of cases (roughly 1 in 5). - **Overdiagnosis** refers to detecting cancers that would not have caused symptoms or death within a patient's lifetime, leading to unnecessary treatment. *Screening reduces breast cancer mortality by approximately 50% in those who attend* - Systematic reviews indicate that screening leads to a relative **reduction in mortality** of approximately **20%**, not 50%. - While substantial, it is crucial not to **overestimate benefit** when providing balanced information for informed consent. *The false positive rate requiring further assessment is less than 2%* - The actual **recall rate** for further assessment (false positives) in the NHS programme is approximately **4-7%**. - False positives can cause significant **psychological distress** and anxiety, which is considered a primary harm of the screening process. *Radiation exposure from screening causes approximately 10 breast cancer cases per 10,000 women screened* - The risk of **radiation-induced cancer** is very low, estimated to cause fewer than **5 additional cases** per 10,000 women screened. - The benefits of detecting existing cancers and **preventing deaths** far outweigh the minimal risk associated with the small dose of radiation in mammography.
Question 120: A 57-year-old man attends for an NHS Health Check. He works night shifts as a security guard and admits to minimal physical activity. His BMI is 32 kg/m², BP 136/84 mmHg, and he has impaired fasting glucose at 6.3 mmol/L. HbA1c is 43 mmol/mol. His QRISK3 score is 9%. He is keen to reduce his diabetes risk. According to NICE guidance, which intervention has the strongest evidence for preventing progression to type 2 diabetes in people with non-diabetic hyperglycaemia?
- A. Metformin 500 mg twice daily
- B. Structured lifestyle modification programme targeting 5-7% weight loss (Correct Answer)
- C. Low-carbohydrate diet with carbohydrate intake <130g daily
- D. Orlistat 120 mg three times daily
- E. Intensive exercise programme of 300 minutes moderate activity per week
Explanation: ***Structured lifestyle modification programme targeting 5-7% weight loss*** - Landmark trials like the **Diabetes Prevention Programme (DPP)** demonstrate that intensive lifestyle changes reduce the risk of progressing to **Type 2 Diabetes** by approximately 58%. - **NICE guidelines** recommend referring patients with non-diabetic hyperglycaemia to structured programmes that combine **dietary changes** and increased **physical activity**. *Metformin 500 mg twice daily* - Although effective, pharmacological intervention with **metformin** typically shows a lower risk reduction (approx. 31%) compared to structured lifestyle changes. - It is usually reserved for patients whose **HbA1c** is rising or failing to improve despite intensive lifestyle interventions, or those with an **HbA1c** ≥ 44 mmol/mol. *Low-carbohydrate diet with carbohydrate intake <130g daily* - While a **low-carbohydrate diet** can assist with glycaemic control, the evidence for a specific carbohydrate threshold is less robust than for **overall weight loss**. - NICE emphasizes a **balanced diet** and total energy deficit rather than specific macronutrient exclusion for the prevention of diabetes. *Orlistat 120 mg three times daily* - **Orlistat** is a weight-loss medication that may indirectly reduce diabetes risk, but it is not recommended as a primary prevention strategy for **non-diabetic hyperglycaemia**. - Its use is specifically targeted at **obesity management** rather than being the first-line intervention for glucose regulation. *Intensive exercise programme of 300 minutes moderate activity per week* - The recommended target for diabetes prevention is generally **150 minutes** of moderate-intensity activity per week, and exercise alone is less effective than **combined diet and exercise**. - **Structured programmes** focus on multifaceted lifestyle changes rather than just high-volume physical activity to ensure sustainable **weight loss**.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free